2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger studyUse of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
Gaidos J, Al Bawardy B, Farraye F, Regueiro M. Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice. Crohn's & Colitis 360 2023, 5: otad037. PMID: 37559746, PMCID: PMC10407976, DOI: 10.1093/crocol/otad037.Peer-Reviewed Original ResearchMayo endoscopic subscoreEndoscopic scoreEndoscopy scoresCrohn's diseaseRutgeerts scoreChi-square testPouchitis Disease Activity IndexDisease activity indexSimple Endoscopic ScoreEndoscopic scoring systemManagement of patientsPearson's chi-square testMore consistent useIBD practiceEndoscopic subscoreMucosal healingAdult gastroenterologistsMore frequent useUnpaired Student'sClinical practiceTreatment targetsScoring systemWeb-based surveyCase-based conferencesFurther evaluationEarly Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis
Sharma S, Li D, Levine L, Chaar A, McMillan C, Gaidos J, Proctor D, Al-Bawardy B. Early Flexible Sigmoidoscopy Improves Clinical Outcomes in Acute Severe Ulcerative Colitis. Crohn's & Colitis 360 2023, 5: otad032. PMID: 37323477, PMCID: PMC10263117, DOI: 10.1093/crocol/otad032.Peer-Reviewed Original ResearchAcute severe ulcerative colitisSevere ulcerative colitisClinical outcomesSigmoidoscopy groupHospital stayFlexible sigmoidoscopyUlcerative colitisIntravenous corticosteroid useRate of colectomyRisk of colectomyHours of admissionOpioid medication useShorter hospital stayCohort of patientsFavorable clinical outcomeLarge prospective studiesRelevant clinical outcomesColectomy rateCorticosteroid useSecondary outcomesMedication usePrimary outcomeProspective studyRetrospective studySigmoidoscopyAssessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows
Al-Bawardy B, Malter L, Ehrlich A, Rieder F, Gaidos J, Proctor D, Windish D. Assessment of Inflammatory Bowel Disease Training Among Gastroenterology Fellows. Inflammatory Bowel Diseases 2023, 29: 1990-1992. PMID: 36810663, PMCID: PMC11491607, DOI: 10.1093/ibd/izad030.Peer-Reviewed Original Research
2024
S1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy
Khan F, Chung S, Kadhim B, Ameyaw P, Fetene J, Dominguez-Diaz A, Al-Bawardy B, Levy A, Proctor D, Gaidos J. S1165 Prevalence and Risk Factors for Ulcerative Colitis Flares After Colonoscopy. The American Journal Of Gastroenterology 2024, 119: s827-s828. DOI: 10.14309/01.ajg.0001034028.79665.88.Peer-Reviewed Original ResearchClinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske H, Ward C, Shah S, Holubar S, Al-Bawardy B, Barnes E, Binion D, Bohm M, Brand M, Clarke K, Cohen B, Cross R, Dueker J, Engels M, Farraye F, Fine S, Forster E, Gaidos J, Ginsburg P, Goyal A, Hanson J, Herfath H, Hull T, Kelly C, Lazarev M, Levy L, Melia J, Philpott J, Qazi T, Siegel C, Watson A, Wexner S, Williams E, Regueiro M. Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE. Crohn's & Colitis 360 2024, 6: otae022. PMID: 38720935, PMCID: PMC11078036, DOI: 10.1093/crocol/otae022.Peer-Reviewed Original ResearchInflammatory bowel diseaseReview of patient historyPresentation of inflammatory bowel diseaseInflammatory bowel disease patientsTreated with biologicsCost of patient careClinical management implicationsReassessment of treatmentIBD specialistsClinical responseMedication-inducedIBD patientsPrescribed steroidsPatient careEndoscopic biopsyTherapeutic workupMultidisciplinary managementIBD casesBalloon enteroscopyAdverse eventsDifferential diagnosisDisease mimicsDiverse presentationsPatient historyBowel diseaseLonger Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2022
Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply